ATTACC CAP

Antithrombotic Therapy to Ameliorate Clinical Complications of Community Acquired Pneumonia

[CTV News Winnipeg @ctvwinnipeg]

Winnipeg-based research project testing out pneumonia treatment https://t.co/NrpSreH5X5

[U of M Rady Faculty @UM_RadyFHS]

Congrats to the UM team awarded $6.9 million by the @CIHR_IRSC to lead an international trial of a steroid drug for pneumonia. The grant will enable expansion of a network of hospital-ward research sites, helping Canada prepare for future pandemics. https://t.co/qADjQZ52pe

[CIHR @CIHR_IRSC]

Today, Minister of Health Mark Holland announced a $43M investment in 14 new Canadian-led #ClinicalTrials to assess treatments and tools with the potential to save lives.

https://t.co/VsAK0kmE1J

[ATTACC CAP @ATTACC_CAP]

We are so excited to expand ATTACC-CAP to include corticosteroids with the introduction of the newly funded DEFEND-CAP domain!

[University of Manitoba @umanitoba]

Exciting news! UM team receives $6.9 million to test pneumonia treatment and expand the network of research sites. Find out more at https://t.co/cOHwNbL5xx

#UManitoba #UMResearch

[ATTACC CAP @ATTACC_CAP]

Such an exciting milestone!

[Sylvain Lother, MD @sylvainlother]

200 patients enrolled in ATTACC-CAP!!
💯 💯

Thanks to all our patient participants, their families, our sites, investigators, coordinators, and large number of partners!

@ATTACC_CAP

[Sylvain Lother, MD @sylvainlother]

200 patients enrolled in ATTACC-CAP!!
💯 💯

Thanks to all our patient participants, their families, our sites, investigators, coordinators, and large number of partners!

@ATTACC_CAP

[Research Manitoba @Research_MB]

We are pleased to announce an investment
of $500K allocated over 5 years designated to support the ATTACC-CAP trail led by @umanitoba researcher @RZarychanski, this will be the second-largest clinical trial led out of Manitoba.
Read full news release: https://t.co/LsO2soXVIq

[Research Manitoba @Research_MB]

Thanks to @N2Canada for creating this infographic all about #InternationalClinicalTrialsDay!

[Sylvain Lother, MD @sylvainlother]

Honored to be recognized as @DoctorsManitoba top 40 under 40! This represents the efforts of a large research team - through COVID and now beyond…. It’s thanks to a productive and enabling team and mentors that we can innovate in medicine, for the benefits of our patients.

[ATTACC CAP @ATTACC_CAP]

Our next phase of ATTACC, ATTACC-CAP, has been generously funded by @Research_MB! Congratulations to our Manitoba PIs @RZarychanski and @sylvainlother

[Research Manitoba @Research_MB]

We are pleased to announce an investment
of $500K allocated over 5 years designated to support the ATTACC-CAP trail led by @umanitoba researcher @RZarychanski, this will be the second-largest clinical trial led out of Manitoba.
Read full news release: https://t.co/LsO2soXVIq

[ATTACC CAP @ATTACC_CAP]

ATTACC PI Dr. Ryan Zarychanski is being recognized as Doctors Manitoba Physician of the Year. Congratulations @RZarychanski! We look forward to your leadership in the next chapter of the ATTACC trial.

[Doctors Manitoba @DoctorsManitoba]

Physician of the Year, Dr. Ryan Zarychanski is being recognized for his truly groundbreaking work leading world-wide efforts to rapidly identify effective COVID-19 treatments. @RZarychanski

[Giovanni Landoni, MD @giovannilandoni]

Thanks to the authors of these 6 high quality RCTs we were able to document that full anticoagulation is improving survival in non-critically-ill #covid19

Swiss COVID-HEP
#PROTHROMCOVID
@ATTACC_COVID
@ACTIV4a
@remap_cap
#RAPIDtrial
@CovidHep
BEMICOP

🔗 https://t.co/fu6cILGQSw

[ATTACC CAP @ATTACC_CAP]

@remap_cap @ACTIV4a @RZarychanski @PatrickLawlerMD @ecgoligher @um_research @UM_RadyFHS @UHN_Research

[ATTACC CAP @ATTACC_CAP]

⬇️ Important summary on the use of antithrombotic agents in patients with COVID-19

[Faizan Khan, PhD @FaizanK91]

🆕 In our @CMAJ paper published today, @TritschlerMD @RZarychanski and I summarize 5 key things to know about antithrombotics in #COVID19.

https://t.co/lrkcG4BaXF

[MayoAntiCoag @MayoAntiCoag]

🔥 This week we'll be discussing the hot topic of VTE Prophylaxis in COVID-19

‼️ Our latest protocol is published on Ask Mayo Expert (AME): https://t.co/IbVK3PFWK0

Go to Inpatient management (adult) ➡️ Inpatient care ➡️ COVID-19 VTE Prophylaxis in Hospitalized Patients

[Matthew D. Neal, MD @macky_neal]

Practice changing work from the #mpRCT and efforts of @ACTIV4a @ATTACC_COVID @remap_cap. @nih_nhlbi @NIH guidelines recommending therapeutic heparin for moderately ill hospitalized patients with #Covid_19 based on our @NEJM papers @NIHCOVIDTxGuide @UPMC @PittTweet

[Ryan Zarychanski @RZarychanski]

A step forward - therapeutic LWMH recommended for hospitalized non-critically I’ll patients with COVID19 @PatrickLawlerMD @ecgoligher @ATTACC_COVID @remap_cap @ACTIV4a @CritCareReviews @accpchest @WHO

[Laveena Munshi @laveenamunshi]

@ecgoligher @PatrickLawlerMD and @RZarychanski present the results of the ATTACC trial, platform trials and the global collaboration involved @CCCForum #CCCF2021 with @JohnGranton1 and @charlot_summers

[CCCF @CCCForum]

#CCCF2021

Keynote address
Monday December 6, 4:45pm

Anticoagulation in COVID-19

by @RZarychanski @ecgoligher @PatrickLawlerMD

https://t.co/UeXKjUo2Yl

[Stephen Lapinsky @StephenLap]

Superb @UofT_DoM Grand Rounds by @ecgoligher & @PatrickLawlerMD on the background, statistical approach & interpretation of the adaptive Bayesian design multiplatform @ATTACC_COVID / @ACTIV4a / @remap_cap anticoag in COVID trial.

https://t.co/zKUKxENPQD
https://t.co/5FQLNzXLaO